Apixaban

Generic Name: Apixaban

Brand Names: Eliquis, Apixaban Accord

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₂₅N_₅O_₄

CAS Number: 503612-47-3

Unique Ingredient Identifier: 3Z9Y7UWC1J

Background: Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases. It is marketed under the name Eliquis. Apixaban was approved by the FDA on December 28, 2012.

Indication: Apixaban is indicated for reducing the risk of stroke and systemic embolism in patients who have nonvalvular atrial fibrillation, prophylaxis of deep vein thrombosis(DVT) leading to pulmonary embolism(PE) in patients after a hip or knee replacement surgery, and treatment of DVT and PE to reduce the risk of recurrence.

Associated Conditions: Deep Vein Thrombosis, Deep vein thrombosis recurrent, Pulmonary Embolism, Recurrent Pulmonary Embolism (Disorder), Stroke, Systemic Embolism

Associated Therapies: -

Clinical Trials

Safety and Effectiveness of Apixaban in Very Elderly Patients With Non-valvular Atrial Fibrillation (NVAF) Compared to Warfarin Using Administrative Claims Data

Completed

Conditions: Non-valvular Atrial Fibrillation

Interventions: Drug: Warfarin
Drug: Apixaban

First Posted Date: 2022-06-30

Last Posted Date: 2024-05-20

Lead Sponsor: Pfizer

Target Recruit Count: 77814

Registration Number: NCT05438888

Locations: 🇯🇵
Pfizer Site, Tokyo, Japan

Safety and Effectiveness of Apixaban Compared to Warfarin in Secondary Prevention in Patients With Atrial Fibrillation

Completed

Conditions: Non-valvular Atrial Fibrillation

Interventions: Drug: Warfarin
Drug: Apixaban

First Posted Date: 2022-04-11

Last Posted Date: 2024-01-11

Lead Sponsor: Pfizer

Target Recruit Count: 193565

Registration Number: NCT05321810

Locations: 🇯🇵
Pfizer, Tokyo, Japan

Prediction of the COBRRA VTE Anticoagulant Trial in Healthcare Claims Data

Completed

Conditions: Pulmonary Embolism
Venous Thromboembolism
DVT

Interventions: Drug: Rivaroxaban
Drug: Apixaban

First Posted Date: 2022-03-03

Last Posted Date: 2023-07-27

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 41875

Registration Number: NCT05264168

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Study to Evaluate the Use of Direct Oral Anticoagulants in UK Clinical Practice For Patients With a First Stroke Attributable to Nonvalvular Atrial Fibrillation

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: Edoxaban
Drug: Apixaban
Drug: Rivaroxaban

First Posted Date: 2022-03-02

Last Posted Date: 2022-07-19

Lead Sponsor: Daiichi Sankyo UK Ltd, a Daiichi Sankyo Company

Target Recruit Count: 234

Registration Number: NCT05262322

Locations: 🇬🇧
Royal Victoria Infirmary - Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, United Kingdom
🇬🇧
Queen Elizabeth University Hospital - NHS Greater Glasgow and Clyde, Glasgow, United Kingdom
🇬🇧
Gloucestershire Royal Hospital - Gloucestershire Hospitals NHS Foundation Trust, Gloucester, United Kingdom

and more 5 locations

Prediction of the COBRRA AF Anticoagulant Trial in Healthcare Claims Data

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: Rivaroxaban
Drug: Apixaban

First Posted Date: 2022-02-25

Last Posted Date: 2023-07-27

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 529536

Registration Number: NCT05256797

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Apixaban in Patients With Left Ventricular Thrombus

Phase 3

Completed

Conditions: Left Ventricular Thrombus

Interventions: Drug: Apixaban
Drug: Warfarin

First Posted Date: 2022-01-26

Last Posted Date: 2022-01-26

Lead Sponsor: Saud Al Babtain Cardiac Center

Target Recruit Count: 50

Registration Number: NCT05208398

Locations: 🇸🇦
Saud AlBabtain Cardiac Center, Dammam, Saudi Arabia

Expanded Access for Apixaban

First Posted Date: 2022-01-11

Last Posted Date: 2022-03-18

Lead Sponsor: Bristol-Myers Squibb

Registration Number: NCT05187286

Locations: 🇺🇸
Childrens Hospital Of Philadelphia, Philadelphia, Pennsylvania, United States

A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE

Phase 3

Recruiting

Conditions: Deep Venous Thrombosis
Pulmonary Embolism
Venous Thromboembolism

Interventions: Drug: Apixaban
Biological: Abelacimab

First Posted Date: 2021-12-28

Last Posted Date: 2024-12-20

Lead Sponsor: Anthos Therapeutics, Inc.

Target Recruit Count: 1655

Registration Number: NCT05171049

Locations: 🇮🇪
Bon Secour Hospital, Cork, Ireland
🇺🇸
University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
🇺🇸
VA Connecticut Healthcare System, West Haven, Connecticut, United States

and more 208 locations

Study of Intravenous VMX-C001 in Healthy Subjects and in Combination With Selected Direct Oral Anticoagulants in Healthy Older Subjects

Phase 1

Completed

Conditions: Coagulation Disorder

Interventions: Drug: VMX-C001
Drug: Placebo
Drug: Apixaban
Drug: Rivaroxaban
Drug: Edoxaban

First Posted Date: 2021-12-09

Last Posted Date: 2023-06-02

Lead Sponsor: VarmX B.V.

Target Recruit Count: 105

Registration Number: NCT05152420

Locations: 🇳🇱
QPS Netherlands B.V., Groningen, Netherlands

Efficacy and Safety of Apixaban in COVID-19 Coagulopathy Patients With Respiratory Severity Under Critical Care

Phase 2

Conditions: COVID-19

Interventions: Drug: Rivaroxaban
Drug: Apixaban

First Posted Date: 2021-10-22

Last Posted Date: 2022-03-10

Lead Sponsor: Scotmann Pharmaceuticals

Target Recruit Count: 40

Registration Number: NCT05088928

Locations: 🇵🇰
Rawalpindi Medical University, Rawalpindi, Punjab, Pakistan

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy